Literature DB >> 24394915

Illuminating p53 function in cancer with genetically engineered mouse models.

Patty B Garcia1, Laura D Attardi2.   

Abstract

The key role of the p53 protein in tumor suppression is highlighted by its frequent mutation in human cancers and by the completely penetrant cancer predisposition of p53 null mice. Beyond providing definitive evidence for the critical function of p53 in tumor suppression, genetically engineered mouse models have offered numerous additional insights into p53 function. p53 knock-in mice expressing tumor-derived p53 mutants have revealed that these mutants display gain-of-function activities that actively promote carcinogenesis. The generation of p53 knock-in mutants with alterations in different domains of p53 has helped further elucidate the cellular and biochemical activities of p53 that are most fundamental for tumor suppression. In addition, modulation of p53 post-translational modification (PTM) status by generating p53 knock-in mouse strains with mutations in p53 PTM sites has revealed a subtlety and complexity to p53 regulation. Analyses of mouse models perturbing upstream regulators of p53 have solidified the notion that the p53 pathway can be compromised by means other than direct p53 mutation. Finally, switchable p53 models that allow p53 reactivation in tumors have helped evaluate the potential of p53 restoration therapy for cancer treatment. Collectively, mouse models have greatly enhanced our understanding of physiological p53 function and will continue to provide new biological and clinical insights in future investigations.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mouse models; Tumor suppression; p53

Mesh:

Substances:

Year:  2014        PMID: 24394915      PMCID: PMC4035469          DOI: 10.1016/j.semcdb.2013.12.014

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  118 in total

Review 1.  Divorcing ARF and p53: an unsettled case.

Authors:  Charles J Sherr
Journal:  Nat Rev Cancer       Date:  2006-08-17       Impact factor: 60.716

2.  Not all p53 gain-of-function mutants are created equal.

Authors:  S S Mello; L D Attardi
Journal:  Cell Death Differ       Date:  2013-07       Impact factor: 15.828

3.  Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity.

Authors:  Yunyuan V Wang; Mathias Leblanc; Norma Fox; Jian-Hua Mao; Kelsey L Tinkum; Kurt Krummel; Dannielle Engle; David Piwnica-Worms; Helen Piwnica-Worms; Allan Balmain; Kenneth Kaushansky; Geoffrey M Wahl
Journal:  Genes Dev       Date:  2011-07-01       Impact factor: 11.361

4.  Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.

Authors:  C Kuperwasser; G D Hurlbut; F S Kittrell; E S Dickinson; R Laucirica; D Medina; S P Naber; D J Jerry
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

5.  Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool.

Authors:  J L Luo; Q Yang; W M Tong; M Hergenhahn; Z Q Wang; M Hollstein
Journal:  Oncogene       Date:  2001-01-18       Impact factor: 9.867

6.  Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage.

Authors:  Gerburg M Wulf; Yih-Cherng Liou; Akihide Ryo; Sam W Lee; Kun Ping Lu
Journal:  J Biol Chem       Date:  2002-10-17       Impact factor: 5.157

7.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

8.  Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD).

Authors:  H G Campbell; R Mehta; A A Neumann; C Rubio; M Baird; T L Slatter; A W Braithwaite
Journal:  Oncogene       Date:  2012-04-09       Impact factor: 9.867

9.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

10.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.

Authors:  T Kamijo; J D Weber; G Zambetti; F Zindy; M F Roussel; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

View more
  23 in total

1.  Sustained protein synthesis and reduced eEF2K levels in TAp73-\- mice brain: a possible compensatory mechanism.

Authors:  Barak Rotblat; Massimiliano Agostini; Maria Victoria Niklison-Chirou; Ivano Amelio; Anne E Willis; Gerry Melino
Journal:  Cell Cycle       Date:  2018-12-04       Impact factor: 4.534

2.  Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer.

Authors:  Yi Zhong; Anne Macgregor-Das; Tyler Saunders; Martin C Whittle; Alvin Makohon-Moore; Zachary A Kohutek; Justin Poling; Brian T Herbst; Breanna M Javier; Leslie Cope; Steven D Leach; Sunil R Hingorani; Christine A Iacobuzio-Donahue
Journal:  Clin Cancer Res       Date:  2016-09-16       Impact factor: 12.531

3.  Homologs of the Tumor Suppressor Protein p53: A Bioinformatics Study for Drug Design.

Authors:  Kelly M Thayer; Claudia Carcamo
Journal:  MOJ Proteom Bioinform       Date:  2020-02-05

4.  Cancer: Mutant p53 and chromatin regulation.

Authors:  Carol Prives; Scott W Lowe
Journal:  Nature       Date:  2015-09-02       Impact factor: 49.962

5.  Combination therapy with atorvastatin and celecoxib delays tumor formation in a Fanconi anemia mouse model.

Authors:  Qing-Shuo Zhang; Matthew Deater; Ngoc Phan; Andrea Marcogliese; Angela Major; Eva C Guinan; Markus Grompe
Journal:  Pediatr Blood Cancer       Date:  2018-09-25       Impact factor: 3.167

Review 6.  A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation.

Authors:  Marina Kazantseva; Sunali Mehta; Ramona A Eiholzer; Noelyn Hung; Anna Wiles; Tania L Slatter; Antony W Braithwaite
Journal:  Mamm Genome       Date:  2018-07-10       Impact factor: 2.957

Review 7.  p53 Acetylation: Regulation and Consequences.

Authors:  Sara M Reed; Dawn E Quelle
Journal:  Cancers (Basel)       Date:  2014-12-23       Impact factor: 6.639

8.  NIAM-deficient mice are predisposed to the development of proliferative lesions including B-cell lymphomas.

Authors:  Sara M Reed; Jussara Hagen; Viviane P Muniz; Timothy R Rosean; Nick Borcherding; Sebastian Sciegienka; J Adam Goeken; Paul W Naumann; Weizhou Zhang; Van S Tompkins; Siegfried Janz; David K Meyerholz; Dawn E Quelle
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

Review 9.  The importance of p53 pathway genetics in inherited and somatic cancer genomes.

Authors:  Giovanni Stracquadanio; Xuting Wang; Marsha D Wallace; Anna M Grawenda; Ping Zhang; Juliet Hewitt; Jorge Zeron-Medina; Francesc Castro-Giner; Ian P Tomlinson; Colin R Goding; Kamil J Cygan; William G Fairbrother; Laurent F Thomas; Pål Sætrom; Federica Gemignani; Stefano Landi; Benjamin Schuster-Böckler; Douglas A Bell; Gareth L Bond
Journal:  Nat Rev Cancer       Date:  2016-04       Impact factor: 60.716

10.  Plakoglobin Reduces the in vitro Growth, Migration and Invasion of Ovarian Cancer Cells Expressing N-Cadherin and Mutant p53.

Authors:  Mahsa Alaee; Ghazal Danesh; Manijeh Pasdar
Journal:  PLoS One       Date:  2016-05-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.